Breaking News

Asher Bio, ProBioGen Ink Development, Mfg. Agreement

ProBioGen to provide cell line development, process development and GMP manufacturing at 1000 L bioreactor scale of Asher's lead immuno-oncology candidate.

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Asher Biotherapeutics, Inc. has entered into a service agreement with ProBioGen AG covering all aspects of cell line development, process development and GMP manufacturing at 1000 L bioreactor scale.   ProBioGen will advance the development of Asher’s lead candidate in immuno-oncology applying its unique transposase technology DirectedLuck which aims to accelerate time-to-clinic.   Asher Biotherapeutics is developing cis-targeted immunotherapies with a new level of selectivity for the ...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters